4.8 Editorial Material

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Ryan C. Ungaro et al.

Summary: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19, while no significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.
Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Gastroenterology & Hepatology

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Nicholas A. Kennedy et al.

Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.
Letter Medicine, General & Internal

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)